Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GBA1-and LRRK2-directed Treatments: The Way Forward.

Parkinsonism & related disorders - 1 May 2024

Maayan Eshed Gadi, Alcalay Roy N

Abstract excerpt

There is an urgent need to identify drug targets for disease modification in Parkinson's Disease (PD). In this mini-review we highlight the reasons genetically-defined drug targets show great promise. Specifically, clinical trials targeting the glucocerebrosidase-1 (GBA1) and leucine-rich repeat kinase 2 (LRRK2) genes are underway. Two key knowledge gaps are 1. How should we modify the GBA1 and LRRK2 pathways?...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glucosylceramidase
Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Parkinson Disease

Source

Identifiers

PMID: 38438297
DOI: 10.1016/j.parkreldis.2024.106039

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GBA1-and LRRK2-directed Treatments: The Way Forward.PMID 38438297Read ↗

Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.Semantic proximity Read ↗

Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson diseaseSemantic proximity Read ↗

GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted TherapySemantic proximity Read ↗

Glucocerebrosidase mutations and Parkinson disease.Semantic proximity Read ↗

Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.Semantic proximity Read ↗

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.Semantic proximity Read ↗

GBA1-Associated Parkinson's Disease Is a Distinct Entity.Semantic proximity Read ↗

Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.Semantic proximity Read ↗

Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism.Semantic proximity Read ↗

GBA Variants and Parkinson Disease: Mechanisms and Treatments.Semantic proximity Read ↗

GBA1-associated parkinsonism: new insights and therapeutic opportunitiesSemantic proximity Read ↗

The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson's Disease: a New Genetic State of the Art.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.